Hadasit Bio Cash Flow Conversion Efficiency

Latest as of June 2022: -0.009x

Hadasit Bio cash flow conversion efficiency. Based on the latest financial reports, Hadasit Bio (HDST) has a cash flow conversion efficiency ratio of -0.009x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-360.50K ≈ $-966.49 USD) by net assets (ILA39.81 Million ≈ $106.73K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Hadasit Bio (2013–2022)

Cash flow conversion efficiency of Hadasit Bio from 2013 to 2022. This chart illustrates how Hadasit Bio's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HDST live share price for real-time trading data and today's change.

Hadasit Bio Cash Flow Conversion Ratio Explained

Hadasit Bio cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Hadasit Bio Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hadasit Bio ranked by their cash flow conversion efficiency. Also see Hadasit Bio stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
France Tourisme Immobilier SA PA:MLFTI	N/A
CrownHaitai Holdings Co Ltd Preference Shares KO:005745	0.045x
Ace Integrated Solutions Limited NSE:ACEINTEG	0.021x
Shrenik Limited NSE:SHRENIK	0.003x
Redcentric LSE:RCN	0.133x
QUHUO LTD SP.ADR/10 CL.A F:9J40	N/A
Bluejay Diagnostics Inc NASDAQ:BJDX	-0.380x
Northern Venture Trust LSE:NVT	-0.025x

Annual Cash Flow Conversion Efficiency for Hadasit Bio (2013–2022)

The table below shows the annual cash flow conversion efficiency of Hadasit Bio from 2013 to 2022. Review HDST free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2022-12-31	ILA35.08 Million ≈ $94.04K	ILA-2.12 Million ≈ $-5.67K	-0.060x	-88.52%
2021-12-31	ILA65.69 Million ≈ $176.12K	ILA-2.10 Million ≈ $-5.63K	-0.032x	+70.05%
2020-12-31	ILA37.11 Million ≈ $99.49K	ILA-3.96 Million ≈ $-10.62K	-0.107x	+81.53%
2019-12-31	ILA5.50 Million ≈ $14.75K	ILA-3.18 Million ≈ $-8.53K	-0.578x	-20.50%
2018-12-31	ILA34.30 Million ≈ $91.96K	ILA-16.46 Million ≈ $-44.12K	-0.480x	-65.93%
2017-12-31	ILA60.79 Million ≈ $162.97K	ILA-17.57 Million ≈ $-47.12K	-0.289x	-21.36%
2016-12-31	ILA61.62 Million ≈ $165.20K	ILA-14.68 Million ≈ $-39.36K	-0.238x	-8.35%
2015-12-31	ILA60.30 Million ≈ $161.66K	ILA-13.26 Million ≈ $-35.55K	-0.220x	+60.29%
2014-12-31	ILA22.11 Million ≈ $59.28K	ILA-12.24 Million ≈ $-32.82K	-0.554x	-18.68%
2013-12-31	ILA24.89 Million ≈ $66.72K	ILA-11.61 Million ≈ $-31.13K	-0.467x	--

About Hadasit Bio

TA:HDST Israel Biotechnology & Medical Research

Market Cap

$1.78 Million

ILA665.31 Million ILA

Market Cap Rank

#30150 Global

#438 in Israel

Share Price

ILA60.00

Change (1 day)

+0.00%

52-Week Range

ILA30.00 - ILA83.00

All Time High

ILA2847.77